Search for other papers by Pernille Bovbjerg in
Google Scholar
PubMed
Search for other papers by Ditte Høgh in
Google Scholar
PubMed
Search for other papers by Lonnie Froberg in
Google Scholar
PubMed
Clinic of Orthopaedic Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Search for other papers by Hagen Schmal in
Google Scholar
PubMed
Search for other papers by Moustapha Kassem in
Google Scholar
PubMed
stimulates bone formation by activating osteoblasts. PTH (1-84) has shown the same effect and has been used as an osteoporotic treatment as well. 5 This suggests a positive influence on bone healing, and teriparatide has been used off-label for treatment
Search for other papers by Pelle V Wall in
Google Scholar
PubMed
Search for other papers by Brendon C Mitchell in
Google Scholar
PubMed
Search for other papers by Canhnghi N Ta in
Google Scholar
PubMed
Search for other papers by William T Kent in
Google Scholar
PubMed
, and risk of thrombosis may complicate their use. Further, these reversal agents are not approved for all DOACs ( 48 ). Prothrombin complex concentrate (PCC) and activated prothrombin complex concentrate (APCC) have also been used off-label for DOAC
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK
Search for other papers by Peter V Giannoudis in
Google Scholar
PubMed
, there have been no studies directly comparing the use of DOAC antidotes to PCC and APCC ( 55 ). Such agents have therefore been typically used in an off-label fashion prior to the invention of the direct antidotes and currently when such antidotes are
